Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.59 |
| ▸ | HTR1A | P08908 | 7/20 | 0.58 |
| ▸ | DRD2 | P14416 | 5/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | HTR7 | P34969 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9484863 | 0.92 | KCNH2 (0.59) | KCNH2CYP2D6SIGMAR1HTR1ADRD2 | |
| SCHEMBL9483832 | 0.87 | KCNH2 (0.74) | KCNH2SIGMAR1HTR1ADRD2HTR2A | |
| SCHEMBL10899538 | 0.85 | DRD2 (0.50) | KCNH2HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL9483819 | 0.84 | HTR1A (0.56) | HTR1ADRD2DRD3DRD4 | |
| SCHEMBL918001 | 0.84 | DRD2 (0.61) | KCNH2SIGMAR1HTR1ADRD2HTR2A | |
| SCHEMBL917906 | 0.84 | DRD2 (0.57) | SIGMAR1HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL13255330 | 0.83 | CCR3 (0.59) | SIGMAR1HTR7DRD4 | |
| SCHEMBL5988317 | 0.82 | KCNH2 (0.88) | KCNH2CYP2D6SIGMAR1HTR1ADRD2 | |
| SCHEMBL9484247 | 0.82 | KDM4E (0.59) | HTR1ADRD2DRD3DRD4 | |
| SCHEMBL9484706 | 0.81 | HRH3 (0.56) | DRD2HTR2ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0278008-B1 | TAURINE TYPE COMPOUNDS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1993-01-20 | — | — | EP | claimed |
| EP-0278008-A1 | TAURINE TYPE COMPOUNDS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-08-17 | — | — | EP | claimed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| EP-1646659-B1 | METHOD FOR THE PREPARATION OF 1,3-PROPANE DISULFONIC ACID COMPOUNDS | KIACTA S RL (CH) | 2014-05-14 | — | — | EP | disclosed |
| EP-1646659-B1 | METHOD FOR THE PREPARATION OF 1,3-PROPANE DISULFONIC ACID COMPOUNDS | KIACTA S RL (CH) | 2014-05-14 | — | — | EP | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| EP-1646659-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | Neurochem (International) Limited (CH) | 2006-04-19 | — | — | EP | disclosed |
| EP-1644325-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-06-30 | — | — | US | disclosed |
| US-20050096385-A1 | Methods and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2005-05-05 | — | — | US | disclosed |
| WO-2004113391-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113275-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-12-29 | — | — | WO | disclosed |
| EP-0278008-B1 | TAURINE TYPE COMPOUNDS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1993-01-20 | — | — | EP | disclosed |
| US-4870078-A | TAURINE-TYPE COMPOUNDS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1989-09-26 | — | — | US | disclosed |
| EP-0278008-A1 | TAURINE TYPE COMPOUNDS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | MPST, TTR, STS | KCNH2 3229/4885CYP2D6 110/4885SIGMAR1 3298/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | KCNH2 3255/4885CYP2D6 3675/4885SIGMAR1 3888/4885 |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | KCNH2 3255/4885CYP2D6 3675/4885SIGMAR1 3888/4885 |
| US-20050096385-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | KCNH2 3255/4885CYP2D6 3675/4885SIGMAR1 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.